Clinical Trial Protocol
Iranian Registry of Clinical Trials

16 Sep 2026

Efficacy of Aspirin in the treatment of schizophrenia

Protocol summary

Summary

The objective of this triple blind randomized clinical trial research is the study of Aspirin efficacy in the treatment of schizophrenia. In this study, 60 schizophrenic patients meeting inclusion and exclusion criteria are randomly assigned into intervention or control group. The patients of intervention group receive Aspirin 1000mg/day while in control group they receive placebo with the same dose and form. PANSS scores will be assessed and compared between groups.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201108197373N1**
Registration date: **2011-10-17, 1390/07/25**
Registration timing: **prospective**

Last update:
Update count: **0**

Registration date

2011-10-17, 1390/07/25

Registrant information

Name
Hamidreza Jamilian
Name of organization / entity
Arak University Of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 86 1222 5758
Email address
jamilian.hr@arakmu.ac.ir

Recruitment status

Recruitment complete

Funding source

Arak University Of Medical Sciences Vice President Of Education And Research

Expected recruitment start date

2011-10-23, 1390/08/01

Expected recruitment end date

2012-05-21, 1391/03/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Efficacy of Aspirin in the treatment of schizophrenia

Public title

Efficacy of Aspirin in the treatment of schizophrenia

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: age range 15-55, diagnosis of schizophrenia according to DSM4-TR criteria and clinical interview by psychiatrist, signing written informed consent, a score of at least 60 in PANSS Exclusion criteria: pregnancy, substance abuse, severe physical disease such as kidney disease, coagulation disorders, GI disorders such as peptic ulcer, contraindications of Aspirin and inhibitors of proton pump

Age

From **15 years** old to **55 years** old

Gender

Both

Phase

1

Groups that have been masked

No information

Sample size

Target sample size: **60**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)
Triple blinded
Blinding description
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Arak University Of Medical Sciences
Street address
Arak University Of Medical Sciences,Basij Square,Sardasht,Arak
City
Arak
Postal code
Approval date
2011-07-06, 1390/04/15
Ethics committee reference number
1-110-90

Health conditions studied

1

Description of health condition studied
Schizophrenia
ICD-10 code
F20
ICD-10 code description
Schizophrenia, schizotypal and delusional disorders.

Primary outcomes

1

Description
PANSS
Timepoint
Before invention and every two weeks
Method of measurement
Clinical examination

Secondary outcomes

1

Description
Extrapyramidal and GI side effect
Timepoint
Before invention and every two weeks
Method of measurement
Clinical examination

Intervention groups

1

Description
Intervention group recieve an atypical antipsychotic plus Aspirin 1000mg/day for 8 weeks
Category
Treatment - Drugs

2

Description
Control group recieve an atypical antipsychotic plus plasebo for 8 weeks (with the same dose and shape).
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Amirkabir Hospital
Full name of responsible person
Dr Hamireza Jamilian
Street address
Amirkabir Hospital
City
Arak

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Arak University Of Medical Sciences
Full name of responsible person
Dr. Ashtiany
Street address
Basij square,Sardasht,University of medical sciences,Arak
City
Arak
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Arak University Of Medical Sciences
Proportion provided by this source
100
Public or private sector
empty
Domestic or foreign origin
empty

Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
empty

Person responsible for general inquiries

Contact

Person responsible for scientific inquiries

Contact
Name of organization / entity
Arak University of Medical Sciences
Full name of responsible person
Dr Hamidreza Jamilian
Position
Board Of Psychiatry
Other areas of specialty/work
Street address
Arak University of Medical Sciences, Basij Square, Sardasht
City
Arak
Postal code
3819691187
Phone
+98 86 1222 5758
Fax
+98 86 1313 2518
Email
Jamilian.Hr@arakmu.ac.ir
Web page address

Person responsible for updating data

Contact

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty
Study Protocol
empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty